MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Aandelen Lijst・Schrodinger Inc

Schrodinger Inc

Gesloten

SectorGezondheidszorg

12.29 1.65

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.26

Max

12.42

Belangrijke statistieken
By Trading Economics
Inkomsten	169M 136M
Verkoop	33M 87M
EPS	-0.18
Winstmarge	155.644
Werknemers	850
EBITDA	67M 36M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+47.89% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	19M 845M
Vorige openingsprijs	10.64
Vorige sluitingsprijs	12.29

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

23.27 / 26.13 Steun & Weerstand

Schrodinger Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 apr 2026, 20:26 UTC

Acquisities, Fusies, Overnames

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 apr 2026, 18:15 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 apr 2026, 16:49 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

18 apr 2026, 01:00 UTC

Belangrijke Nieuwsgebeurtenissen

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 apr 2026, 22:58 UTC

Winsten

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 apr 2026, 21:32 UTC

Marktinformatie

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 apr 2026, 21:22 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 apr 2026, 21:22 UTC

Marktinformatie

Moody's Downgrades Belgium to A1 -- Market Talk

17 apr 2026, 20:52 UTC

Winsten

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

17 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 apr 2026, 20:29 UTC

Winsten

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 apr 2026, 20:11 UTC

Acquisities, Fusies, Overnames

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 apr 2026, 19:34 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

17 apr 2026, 19:34 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 apr 2026, 19:31 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 apr 2026, 19:26 UTC

Marktinformatie

U.S. Natural Gas Futures Edge Up -- Market Talk

17 apr 2026, 19:21 UTC

Marktinformatie

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 apr 2026, 19:15 UTC

Marktinformatie

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 apr 2026, 19:07 UTC

Marktinformatie

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 apr 2026, 18:57 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 apr 2026, 18:53 UTC

Acquisities, Fusies, Overnames

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 apr 2026, 18:53 UTC

Acquisities, Fusies, Overnames

UCB 2026 Rev Guidance Unchanged

17 apr 2026, 18:52 UTC

Acquisities, Fusies, Overnames

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 apr 2026, 18:52 UTC

Acquisities, Fusies, Overnames

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 apr 2026, 18:14 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 apr 2026, 18:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 apr 2026, 18:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 apr 2026, 17:31 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 apr 2026, 17:26 UTC

Marktinformatie

Winsten

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Peer Vergelijking

Prijswijziging

Schrodinger Inc Prognose

Koersdoel

By TipRanks

47.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.25 USD 47.89%

Hoogste 20 USD

Laagste 13 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Schrodinger Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Schrodinger Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

23.27 / 26.13Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.